Literature DB >> 27206848

Membrane IL1α Inhibits the Development of Hepatocellular Carcinoma via Promoting T- and NK-cell Activation.

Dandan Lin1, Lei Lei1, Yonghao Liu1, Yinsheng Zhang1, Bo Hu1, Guangming Bao1, Yuan Song1, Ziqi Jin1, Chunliang Liu2, Yu Mei3, Dedy Sandikin4, Yan Wu1, Lixiang Zhao1, Xiao Yu1, Haiyan Liu5.   

Abstract

Hepatocellular carcinoma is a worldwide health problem with limited treatment options and poor prognosis. Inflammation associated with liver injury and hepatocyte regeneration can lead to fibrosis, cirrhosis, and eventually, hepatocellular carcinoma. IL1α is one of the most important inflammatory cytokines involved in inflammation and tumor development. IL1α presents as multiple forms in vivo, including precursor, propiece, membrane, and secreted forms, and their functions have been thought to be different. The role of membrane IL1α in hepatocellular carcinoma tumorigenesis is still not clear. Here, we examined the functions of membrane IL1α in murine hepatocellular carcinoma models. We found that membrane IL1α potently inhibited hepatocellular carcinoma tumor growth. Further studies showed that membrane IL1α promoted T- and natural killer (NK)-cell activation in vivo IFNγ production by CD8(+) T and NK cells was also increased as a result of membrane IL1α expression. Moreover, the cytotoxicity of the CTL and NK cells was also enhanced by membrane IL1α expression. Furthermore, in vitro studies demonstrated that membrane IL1α could directly activate T cells and NK cells in a cell contact-dependent manner. Conversely, depletion of both CD8(+) T and NK cells suppressed the antitumor activity of membrane IL1α. Our studies demonstrated that membrane IL1α could promote antitumor immune responses through activation of T and NK cells. Thus, our findings provide new insights of IL1α functions during hepatocellular carcinoma development. Cancer Res; 76(11); 3179-88. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27206848     DOI: 10.1158/0008-5472.CAN-15-2658

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach.

Authors:  Faezeh Hosseinzadeh; Jafar Ai; Abbas Hajifathali; Samad Muhammadnejad; Somayeh Ebrahimi-Barough; Iman Seyhoun; Tahereh Komeili Movahed; Sadegh Shirian; Fatemeh Hosseinzadeh; Sajjad Ahmadpour; Mohammadreza Alijani; Javad Verdi
Journal:  Pharmacol Rep       Date:  2022-01-28       Impact factor: 3.024

2.  Immune suppressive function of IL-1α release in the tumor microenvironment regulated by calpain 1.

Authors:  Dandan Lin; Yu Mei; Lei Lei; Zuhairah Binte Hanafi; Ziqi Jin; Yonghao Liu; Yuan Song; Yinsheng Zhang; Bo Hu; Chunliang Liu; Jinhua Lu; Haiyan Liu
Journal:  Oncoimmunology       Date:  2022-06-15       Impact factor: 7.723

3.  Overexpression of Interleukin-1α Suppresses Liver Metastasis of Lymphoma: Implications for Antitumor Effects of CD8+ T-cells.

Authors:  Kazuhiko Udagawa; Yasuo Niki; Toshiyuki Kikuchi; Yusuke Fukuhara; Yuki Takeda; Takeshi Miyamoto; Morio Matsumoto; Masaya Nakamura
Journal:  J Histochem Cytochem       Date:  2021-02-09       Impact factor: 2.479

4.  Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis.

Authors:  Xiang Yu; Lu Chen; Jianqiao Liu; Bolei Dai; Guoqiang Xu; Guanxin Shen; Qingming Luo; Zhihong Zhang
Journal:  Nat Commun       Date:  2019-02-04       Impact factor: 14.919

5.  Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.

Authors:  Madelyn Espinosa-Cotton; Samuel N Rodman Iii; Kathleen A Ross; Isaac J Jensen; Kenley Sangodeyi-Miller; Ayana J McLaren; Rachel A Dahl; Katherine N Gibson-Corley; Adam T Koch; Yang-Xin Fu; Vladimir P Badovinac; Douglas Laux; Balaji Narasimhan; Andrean L Simons
Journal:  J Immunother Cancer       Date:  2019-03-19       Impact factor: 13.751

6.  CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism.

Authors:  Jean-Philippe Guégan; Justine Pollet; Christophe Ginestier; Emmanuelle Charafe-Jauffret; Marcus E Peter; Patrick Legembre
Journal:  iScience       Date:  2021-12-01

7.  The Notch Signaling Pathway Is Balancing Type 1 Innate Lymphoid Cell Immune Functions.

Authors:  Thibaut Perchet; Maxime Petit; Elena-Gaia Banchi; Sylvain Meunier; Ana Cumano; Rachel Golub
Journal:  Front Immunol       Date:  2018-06-07       Impact factor: 7.561

8.  c-Jun-dependent β3GnT8 promotes tumorigenesis and metastasis of hepatocellular carcinoma by inducing CD147 glycosylation and altering N-glycan patterns.

Authors:  Chunliang Liu; Hao Qiu; Dandan Lin; Zerong Wang; Ning Shi; Zengqi Tan; Jun Liu; Zhi Jiang; Shiliang Wu
Journal:  Oncotarget       Date:  2018-01-12

9.  IL-1α correlates with severity of hepatitis C virus-related liver diseases.

Authors:  Ahmed Khaled Tawfik; Ahmed Mustafa Amin; Mohamed Yousef; Noha Mohamed El-Sayd; Heba Elashry; Mahmoud Elkadeem; Sherief Abd-Elsalam
Journal:  J Inflamm Res       Date:  2018-07-10

Review 10.  Cellular based immunotherapy for primary liver cancer.

Authors:  Yuanyuan Zheng; Yan Li; Jiao Feng; Jingjing Li; Jie Ji; Liwei Wu; Qiang Yu; Weiqi Dai; Jianye Wu; Yingqun Zhou; Chuanyong Guo
Journal:  J Exp Clin Cancer Res       Date:  2021-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.